Evidence that α2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: A new role for plasma factor XIII in fibrinolysis regulation

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 9, 2008, Pages 1565-1570

  Mosesson, Michael W ^a   Siebenlist, K R ^b   Hernandez, I ^a   Lee, K N ^c   Christiansen, V J ^c   Mckee, P A ^c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MARQUETTE UNIVERSITY   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

alpha; 2 antiplasmin; Factor XIII; Fibrinogen; Fibrinolysis; Serpin

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 8; FIBRIN; FIBRINOGEN; IODINE 125; ANTIPLASMIN; BLOOD CLOTTING FACTOR 13;

ARTICLE; CATALYSIS; CIRCULATION; CONTROLLED STUDY; COVALENT BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; IMMUNOASSAY; METABOLISM; PHYSIOLOGY;

ANTIPLASMIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIII; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; IMMUNOASSAY;

EID: 49849101064     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03056.x     Document Type: Article

References (40)

1. Aoki H, Harpel PC. Inhibitors in the fibrinolytic enzyme system. Semin Thromb Haemost 1984; 10: 24-41.
2. Collen D. Identification and some properties of a new fast reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
3. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-65.
4. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-53.
5. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-84.
6. Aoki N, Sakata Y. Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin. Thromb Res 1980; 19: 149-55.
7. Saito H. Alpha 2-plasmin inhibitor and its deficiency states. J Lab Clin Med 1988; 112: 671-8.
8. Kimura S, Aoki N. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
9. Ritchie H, Lawrie LC, Crombie PW, Mosesson MW, Booth NA. Cross-linking of plasminogen activator inhibitor 2 and {alpha}2- antiplasmin to fibrin(ogen). J Biol Chem 2000; 275: 24915-20.
10. Moroi M, Aoki N. On the interaction of alpha2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bondings between the inhibitor and proteases. Biochim Biophys Acta 1977; 482: 412-20.
11. Aoki N, Moroi M, Tachiya K. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin. Thromb Haemost 1978; 39: 22-31.
12. 2 -plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
13. Weitz JI, Leslie B, Hirsh J, Klement P. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest 1993; 91: 1343-50.
14. Lee AY, Fredenburgh JC, Stewart RJ, Rischke JA, Weitz JI. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin. Thromb Haemost 2001; 85: 502-8.
15. 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280-6.
16. Ichinose A, Aoki N. Reversible cross-linking of alpha 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 1982; 706: 158-64.
17. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
18. Koyama T, Koike Y, Toyota S, Miyagi F, Suzuki N, Aoki N. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
19. Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993; 291 (Pt 2): 623-5.
20. Christiansen VJ, Jackson KW, Lee KN, McKee PA. The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity. Blood 2007; 109: 5286-92.
21. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
22. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem (Tokyo) 1989; 106: 703-7.
23. Mosesson MW, Finlayson JS. Biochemical and chromatographic studies of certain activities associated with human fibrinogen preparations. J Clin Invest 1963; 42: 747-55.
24. Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11: 293-304.
25. Siebenlist KR, Meh D, Mosesson MW. Protransglutaminase (factor XIII) mediated crosslinking of fibrinogen and fibrin. Thromb Haemost 2001; 86: 1221-8.
26. Mosesson MW, Sherry S. The preparation and properties of human fibrinogen of relatively high solubility. Biochemistry 1966; 5: 2829-35.
27. Siebenlist KR, Mosesson MW. Evidence for intramolecular cross-linked Aαγ chain heterodimers in plasma fibrinogen. Biochemistry 1996; 35: 5817-21.
28. Mosesson MW, Galanakis DK, Finlayson JS. Comparison of human plasma fibrinogen subfractions and early plasmic fibrinogen derivatives. J Biol Chem 1974; 249: 4656-64.
29. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann NY Acad Sci 1983; 408: 28-43.
30. Veklich YI, Gorkun OV, Medved LV, Niewenhuizen W, Weisel JW. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. J Biol Chem 1993; 268: 13577-85.
31. Lorand L, Gotoh T. Fibrinoligase. The fibrin stabilizing factor. Methods Enzymol 1970; 19: 770-82.
32. Loewy AG, Dunathan K, Kriel R, Wolfinger HL. Fibrinase I. Purification of substrate and enzyme. J Biol Chem 1961; 236: 2625-33.
33. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-407.
34. Lee KN, Lee CS, Tae WC, Jackson KW, Chistiansen VJ, McKee PA. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275: 37382-9.
35. Martin BE, Wasiewski WW, Fenton JW II, Detwiler TC. Equillibrium binding of thrombin to platelets. Biochemistry 1976; 15: 4886-93.
36. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
37. Mosesson MW, Hernandez I, Raife TJ, Medved L, Yakovlev S, Simpson-Haidaris PJ, Uitte de Willige S, Bertina R. Plasma fibrinogen gamma'chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2007; 5: 62-9.
38. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
39. Mosesson MW, Wautier JL, Amrani DL, Dervichian M, Cattan D. Evidence for circulating fibrin in familial Mediterranean fever. J Lab Clin Med 1982; 99: 559-67.
40. Mosesson MW, Colman RW, Sherry S. Chronic intravascular coagulation syndrome. N Engl J Med 1968; 278: 815-21.